FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029111322> ?p ?o ?g. }

• W2029111322 endingPage "S214" @default.
• W2029111322 startingPage "S213" @default.
• W2029111322 abstract "Adjuvant pelvic external beam radiotherapy (EBRT) has been found to decrease the rate of pelvic and vaginal recurrence after surgery for Stage I endometrial cancer. However, pelvic EBRT may be unnecessary treatment for pathologic Stage I endometrial cancer for patients who undergo complete surgical staging. Because most recurrences after surgery occur at the vaginal cuff, treating the vaginal cuff alone may be sufficiently effective and potentially less toxic than pelvic EBRT. Most adjuvant high dose rate brachytherapy (HDR) studies thus far have included patients without complete surgical staging. The purpose of this study is to determine the efficacy and complication rate of adjuvant HDR brachytherapy alone for patients with Stage I endometrial cancer having undergone complete surgical staging. Between April 1998 and March 2004, 100 patients with Stage I endometrial cancer underwent complete surgical staging (TAH/BSO and pelvic ± para-aortic lymph node sampling) followed by post-operative vaginal cuff HDR brachytherapy at our institution. 73% had endometrioid (or unspecified) adenocarcinoma, 16% had papillary serous carcinoma, and 11% had other histologies (adenosquamous, clear cell, MMT, and mixed histologies). Most patients (94%) were either FIGO IB (N = 54) or IC (N = 40). Five were FIGO IA and 1 had unspecified depth of myometrial invasion. All IA patients were grade III. Of the IB patients, 6, 27, and 20 were grade I, II, and III, respectively. Of the IC patients, 13, 17, and 10 were grade I, II, and III, respectively. One IB patient had unspecified grade and the patient with unspecified substage was grade II. The mean maximum tumor diameter was 3.9 cm. Lymphovascular invasion (LVI) was included in 23% of pathology reports and, of these, 3 patients had LVI. Five patients (all with papillary serous carcinoma) were treated with adjuvant chemotherapy. Typically, 3 HDR fractions x 700 cGy each were delivered to a depth of 5–7mm from the vaginal mucosa using a multiple channel cylinder and Nucletron mHDR afterloading device. All patients had a pelvic lymph node dissection and 42% had a para-aortic node dissection. A median of 29.5 (range, 1–67) pelvic nodes were removed (84% had >10 pelvic nodes removed) and a median of 10.5 (range, 1–35) para-aortic nodes were removed. The mean number of days between the first and last HDR treatments was 14.7. The total dose was 2100 cGy in 95% of patients. With a median follow-up of 23 months (range, 1–62), there were no pelvic or vaginal recurrences. Three patients developed distant metastases. The peritoneal cytology from one patient who developed omental and lung metastases originally had cells suspicious, but not diagnostic, for malignancy. One patient developed retroperitoneal metastases and died. One patient developed peritoneal metastases and is still alive. Two patients died from other causes; one from acute myeloid leukemia that evolved from essential thrombocythemia, and one from an unidentified cause. Thirty-nine percent of patients had no side effects. Most side effects were mild (CTC grade 1–2) and consisted of vaginal cuff telangiectasias (14%), vaginal atrophy, stricture, or adhesions (16%), dyspareunia (5%), temporary urinary irritation (9%), and temporary diarrhea (9%). Four patients had mild intermittent urinary incontinence after treatment, possibly related to surgery, brachytherapy, or other factors. There was one cuff dehiscence from applicator placement that healed spontaneously. Adjuvant HDR brachytherapy alone is effective and has minimal side effects for patients with surgical Stage I endometrial cancer. At our institution, patients underwent an extensive lymph node sampling/dissection and there were no vaginal or pelvic recurrences after vaginal cuff brachytherapy alone. Thus, for similar patients, HDR brachytherapy alone is a safe and effective alternative to pelvic EBRT" @default.
• W2029111322 created "2016-06-24" @default.
• W2029111322 creator A5046346119 @default.
• W2029111322 creator A5051643444 @default.
• W2029111322 creator A5071942279 @default.
• W2029111322 date "2004-09-01" @default.
• W2029111322 modified "2023-09-25" @default.
• W2029111322 title "Vaginal cuff HDR brachytherapy alone is sufficient adjuvant treatment for patients with surgical stage I endometrial cancer" @default.
• W2029111322 doi "https://doi.org/10.1016/j.ijrobp.2004.06.164" @default.
• W2029111322 hasPublicationYear "2004" @default.
• W2029111322 type Work @default.
• W2029111322 sameAs 2029111322 @default.
• W2029111322 citedByCount "4" @default.
• W2029111322 countsByYear W20291113222013 @default.
• W2029111322 crossrefType "journal-article" @default.
• W2029111322 hasAuthorship W2029111322A5046346119 @default.
• W2029111322 hasAuthorship W2029111322A5051643444 @default.
• W2029111322 hasAuthorship W2029111322A5071942279 @default.
• W2029111322 hasBestOaLocation W20291113221 @default.
• W2029111322 hasConcept C121608353 @default.
• W2029111322 hasConcept C126322002 @default.
• W2029111322 hasConcept C126838900 @default.
• W2029111322 hasConcept C141071460 @default.
• W2029111322 hasConcept C146357865 @default.
• W2029111322 hasConcept C151730666 @default.
• W2029111322 hasConcept C2775908122 @default.
• W2029111322 hasConcept C2777088508 @default.
• W2029111322 hasConcept C2777416452 @default.
• W2029111322 hasConcept C2777546739 @default.
• W2029111322 hasConcept C2779494336 @default.
• W2029111322 hasConcept C2780849966 @default.
• W2029111322 hasConcept C509974204 @default.
• W2029111322 hasConcept C71924100 @default.
• W2029111322 hasConcept C86803240 @default.
• W2029111322 hasConceptScore W2029111322C121608353 @default.
• W2029111322 hasConceptScore W2029111322C126322002 @default.
• W2029111322 hasConceptScore W2029111322C126838900 @default.
• W2029111322 hasConceptScore W2029111322C141071460 @default.
• W2029111322 hasConceptScore W2029111322C146357865 @default.
• W2029111322 hasConceptScore W2029111322C151730666 @default.
• W2029111322 hasConceptScore W2029111322C2775908122 @default.
• W2029111322 hasConceptScore W2029111322C2777088508 @default.
• W2029111322 hasConceptScore W2029111322C2777416452 @default.
• W2029111322 hasConceptScore W2029111322C2777546739 @default.
• W2029111322 hasConceptScore W2029111322C2779494336 @default.
• W2029111322 hasConceptScore W2029111322C2780849966 @default.
• W2029111322 hasConceptScore W2029111322C509974204 @default.
• W2029111322 hasConceptScore W2029111322C71924100 @default.
• W2029111322 hasConceptScore W2029111322C86803240 @default.
• W2029111322 hasIssue "1" @default.
• W2029111322 hasLocation W20291113221 @default.
• W2029111322 hasOpenAccess W2029111322 @default.
• W2029111322 hasPrimaryLocation W20291113221 @default.
• W2029111322 hasRelatedWork W1968799611 @default.
• W2029111322 hasRelatedWork W1981573615 @default.
• W2029111322 hasRelatedWork W2069132912 @default.
• W2029111322 hasRelatedWork W2085490436 @default.
• W2029111322 hasRelatedWork W2322172419 @default.
• W2029111322 hasRelatedWork W2411961033 @default.
• W2029111322 hasRelatedWork W2591675905 @default.
• W2029111322 hasRelatedWork W2993575405 @default.
• W2029111322 hasRelatedWork W3023151437 @default.
• W2029111322 hasRelatedWork W4295234634 @default.
• W2029111322 hasVolume "60" @default.
• W2029111322 isParatext "false" @default.
• W2029111322 isRetracted "false" @default.
• W2029111322 magId "2029111322" @default.
• W2029111322 workType "article" @default.